Atopic dermatitis (AD) has become a global health concern, with a worldwide incidence of 2.1% to 4.9% in adults, and it continues to rise , especially in developing countries. For this chronic and relapsing disease , conventional treatments include:

1. Externally applied moisturizing emollients to restore skin barrier function.
2. Topical corticosteroids (TCS) to quickly and efficiently control inflammation and alleviate symptoms.
3. Immunosuppressive agents for patients with severe AD.

genetically engineered animal Innovative AD-specific medicine is a very popular research topic. Dupilumab can suppress the inflammatory response by blocking IL-4 and IL-13 signaling, while Trastuzumab is the first FDA-approved drug to bind to IL-13 and decrease its activity selectively. In addition, several JAK inhibitors, including Baricitinib, Upatinib, and Abrocitinib, can be used to treat AD. Potential targets and strategies continue to generate fresh approaches for developing AD medications.

Selecting suitable animal models for in vivo research during early drug screening could accelerate later clinical trials. Our team has developed a protocol for the construction and validation of oxazolone (OXA)-induced AD models for preclinical drug discovery and efficacy evaluation of AD therapeutics.

Figure 1 OXA-induced AD mouse modeling and preclinical testing scheme

https://en.gempharmatech.com/product/models_list100139_170121.html